Kenneth R. Chapman, MD, MSc, FRCPC, FACP, FCCP, FERS
University of Toronto; Toronto, ON

Session Description

Beginning this year, Canadian Blood Services will make intravenous augmentation therapy available to all Canadians with emphysema secondary severe alpha-1 antitrypsin deficiency.  This presentation will review the medical science behind this decision and examine the strategies all Canadian pulmonary physicians must master to detect and treat this disorder.

Learning Objectives

At the end of this presentation, attendees will be able to:

  • Devise appropriate screening strategies to identify the patients in their practice with alpha-1 antitrypsin deficiency.
  • Understand the role and prescribing guidelines for augmentation therapy.
  • Identify regional expertise for assistance with clinical challenges in alpha-1 antitrypsin deficiency.

CanMEDS Roles: Communicator, Medical Expert, Scholar